Bioxytran Depreciation & Amortization Growth & History (BIXT)
Bioxytran's depreciation and amortization was $11,544 for fiscal 2025.
View full Bioxytran company overviewBioxytran annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11,544 | $3,594 | +45.21% |
| 2024 | 2024-12-31 | $7,950 | −$335 | −4.04% |
| 2023 | 2023-12-31 | $8,285 | $4,641 | +127.36% |
| 2022 | 2022-12-31 | $3,644 | — | — |
| 2017 | 2017-12-31 | $17,536 | −$10,092 | −36.53% |
| 2016 | 2016-12-31 | $27,628 | −$27,152 | −49.57% |
| 2015 | 2015-12-31 | $54,780 | −$3,411 | −5.86% |
| 2014 | 2014-12-31 | $58,191 | $7,134 | +13.97% |
| 2013 | 2013-12-31 | $51,057 | $10,414 | +25.62% |
| 2012 | 2012-12-31 | $40,643 | $9,987 | +32.58% |
| 2011 | 2011-12-31 | $30,656 | $27,245 | +798.74% |
| 2010 | 2010-12-31 | $3,411 | — | — |
Bioxytran quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5,580 | $5,580 | — |
| Q1 2026 | 2026-03-31 | $2,108 | $257 | +13.88% |
| Q4 2025 | 2025-12-31 | $2,948 | — | — |
| Q3 2025 | 2025-09-30 | $6,745 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $1,851 | — | — |
| Q2 2018 | 2018-06-30 | $4,363 | −$69 | −1.56% |
| Q1 2018 | 2018-03-31 | $4,363 | $0 | 0.00% |
| Q3 2017 | 2017-09-30 | $4,377 | −$310 | −6.61% |
| Q2 2017 | 2017-06-30 | $4,432 | −$2,449 | −35.59% |
| Q1 2017 | 2017-03-31 | $4,363 | −$7,230 | −62.37% |
| Q3 2016 | 2016-09-30 | $4,687 | −$9,861 | −67.78% |
| Q2 2016 | 2016-06-30 | $6,881 | −$7,667 | −52.70% |
| Q1 2016 | 2016-03-31 | $11,593 | −$2,954 | −20.31% |
| Q3 2015 | 2015-09-30 | $14,548 | $0 | 0.00% |
| Q2 2015 | 2015-06-30 | $14,548 | $0 | 0.00% |
| Q1 2015 | 2015-03-31 | $14,547 | $0 | 0.00% |
| Q3 2014 | 2014-09-30 | $14,548 | −$8,400 | −36.60% |
| Q2 2014 | 2014-06-30 | $14,548 | $11,966 | +463.44% |
| Q1 2014 | 2014-03-31 | $14,547 | $4,365 | +42.87% |
| Q3 2013 | 2013-09-30 | $22,948 | $2,642 | +13.01% |
| Q2 2013 | 2013-06-30 | $2,582 | −$7,563 | −74.55% |
| Q1 2013 | 2013-03-31 | $10,182 | $37 | +0.36% |
| Q3 2012 | 2012-09-30 | $20,306 | $12,660 | +165.58% |
| Q2 2012 | 2012-06-30 | $10,145 | $3,561 | +54.09% |
| Q1 2012 | 2012-03-31 | $10,145 | $5,604 | +123.41% |
| Q3 2011 | 2011-09-30 | $7,646 | $6,808 | +812.41% |
| Q2 2011 | 2011-06-30 | $6,584 | — | — |
| Q1 2011 | 2011-03-31 | $4,541 | — | — |
| Q3 2010 | 2010-09-30 | $838 | — | — |
Bioxytran depreciation and amortization trends
Between the periods ended 2010-12-31 and 2025-12-31, Bioxytran's depreciation and amortization increased from $3,411 to $11,544, a change of $8,133. The latest reported quarter, Q2 2026, shows $5,580.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioxytran source filings ↗